Evidence map›Paper›PMID 38575714›Full record

ArticleCommunications medicine2024

Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response.

Martina Esposito, Francesca Minnai, Massimiliano Copetti, Giuseppe Miscio, Rita Perna, Ada Piepoli, Gabriella De Vincentis, Mario Benvenuto, Paola D'Addetta, Susanna Croci and 15 more

Open access · goldAbstract read
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Frontiers in immunology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 2 countries.

Martina EspositoNational Research Council, Institute for Biomedical Technologies, Segrate, MI, Italy.ORCID http://orcid.org/0009-0007-4118-3893
Francesca MinnaiNational Research Council, Institute for Biomedical Technologies, Segrate, MI, Italy.
Massimiliano CopettiFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.ORCID http://orcid.org/0000-0002-7960-5947
Giuseppe MiscioFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Rita PernaFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Ada PiepoliFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Gabriella De VincentisFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Mario BenvenutoFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.ORCID http://orcid.org/0000-0002-3186-0199
Paola D'AddettaFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Susanna CrociMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Margherita BaldassarriMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Mirella BruttiniMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Chiara FalleriniMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Raffaella BrugnoniFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID http://orcid.org/0000-0003-1365-4508
Paola CavalcanteFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Fulvio BaggiFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID http://orcid.org/0000-0002-4618-0102
Elena Maria Grazia CorsiniFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID http://orcid.org/0000-0001-8080-6976
Emilio CiusaniFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Francesca AndreettaFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID http://orcid.org/0000-0001-8239-8830
Tommaso A DraganiAspidia srl, Milan, Italy.
Maddalena FratelliIstituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-1769-3427
Massimo CarellaFondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.
Renato E MantegazzaFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Alessandra RenieriMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0002-0846-9220
Francesca ColomboNational Research Council, Institute for Biomedical Technologies, Segrate, MI, Italy. francesca.colombo@cnr.it.ORCID http://orcid.org/0000-0003-2015-4317
Casa Sollievo della Sofferenza · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITUniversity of Siena · ITNational Academies of Sciences, Engineering, and Medicine · USMario Negri Institute for Pharmacological Research · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the beginning of the anti-COVID-19 vaccination campaign, it has become evident that vaccinated subjects exhibit considerable inter-individual variability in the response to the vaccine that could be partly explained by host genetic factors. A recent study reported that the immune response elicited by the Oxford-AstraZeneca vaccine in individuals from the United Kingdom was influenced by a specific allele of the human leukocyte antigen gene HLA-DQB1.

methodsWe carried out a genome-wide association study to investigate the genetic determinants of the antibody response to the Pfizer-BioNTech vaccine in an Italian cohort of 1351 subjects recruited in three centers. Linear regressions between normalized antibody levels and genotypes of more than 7 million variants was performed, using sex, age, centers, days between vaccination boost and serological test, and five principal components as covariates. We also analyzed the association between normalized antibody levels and 204 HLA alleles, with the same covariates as above.

resultsOur study confirms the involvement of the HLA locus and shows significant associations with variants in HLA-A, HLA-DQA1, and HLA-DQB1 genes. In particular, the HLA-A*03:01 allele is the most significantly associated with serum levels of anti-SARS-CoV-2 antibodies. Other alleles, from both major histocompatibility complex class I and II are significantly associated with antibody levels.

conclusionsThese results support the hypothesis that HLA genes modulate the response to Pfizer-BioNTech vaccine and highlight the need for genetic studies in diverse populations and for functional studies aimed to elucidate the relationship between HLA-A*03:01 and CD8+ cell response upon Pfizer-BioNTech vaccination.

Identifiers

PMID38575714
PMCPMC10995155
OpenAlexW4393932811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.